Indeed, it has been reported that expression of PD-L1 on circulating T cells is higher in melanoma patients compared to healthy donors, and patients with lower baseline levels of circulating PD-L1+ CD4+ and CD8+ T cells respond better to ipilimumab [244]. The gene discussed is CD274; the disease is melanoma.